Brain Tumor Diagnosis and Therapeutics Market Size Worth $6.60 Billion By 2030 | CAGR: 10.3%

The global brain tumor diagnosis and therapeutics market size are expected to reach USD 6.60 billion by 2030 according to a new study by Polaris Marker Research. The report “Brain Tumor Diagnosis and Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (Primary {Meningiomas, Gliomas, Astrocytoma’s, Pituitary Tumors, Others}, Secondary); By Diagnosis; By Therapeutics; By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

A surge in cancer cases with increasing awareness and error-free diagnosis procedures, particularly in the developed nations, are primarily responsible for market growth. According to the World Cancer Research Fund International, in 2020, head cancer cases make up 1.7% of all types of cancers worldwide, with a total number of 308,102 head cancer cases, out of which 168,346 cases are in men and 139,756 cases in women. Furthermore, The factors that propel the development of the therapeutics market are the rising geriatric population, imbalanced lifestyles, advances in R&D advances, and increasing post-treatment side effects among the populace.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/global-brain-tumor-diagnosis-and-therapeutics-market/request-for-sample

Glioblastomas are considered one of the most common types with aggressive growth and are continually recognized as 4-grade cancer. Every year, 14,000 glioblastoma cases are diagnosed by doctors in the U.S. The average age of people diagnosed with a lump is 50-64. Primary glioblastoma makes up around 90% of cases based on the types. Treatment includes regular chemotherapy sessions and proper doses of drugs like temozolomide, Carmustine (BCNU), and Lomustine (CCNU).

There have been seen increasing cases of brain cancers in the U.S. According to the Brain Tumor Society, around 700,000 people in the U.S. are suffering from primary brain lumps, and estimated that in 2022, approximately 88,970 people would be diagnosed.

Brain Tumor Diagnosis and Therapeutics Market Report Highlights

• PC tomography is considered one of the effective treatments due to its higher reach to the cancerous tissues growing inside the body.
• The MRI coupled with the CT- scan for the identification of lumps while the patient is undergoing treatment.
• The primary segment accounts for a significant share in the market due to the increasing cases worldwide.
• Surgery section to hold one of the most significant market shares during the forecast period due to the unavailability of proper medications for the treatment of fourth-stage brain tumors
• Market participants include AstraZeneca., Amgen Inc., Bayer AG, Carestream Health, Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co, Siemens Healthineers, Eisai Inc., Fujifilm Corporation, GE Healthcare Inc., Hitachi, Pfizer Inc., Philips Healthcare, GlaxoSmithKline PLC, Shimadzu Corporation, and Toshiba Corporation

Polaris Market Research has segmented the brain tumor diagnosis and therapeutics market report based on type, diagnosis, therapeutics, and region:

Brain Tumor Diagnosis and Therapeutics Type Outlook (Revenue - USD Billion, 2018 - 2030)

• Primary
  • Meningioma
  • Gliomas
  • Astrocytomas
  • Pituitary Tumors
  • Others
• Secondary

Brain Tumor Diagnosis and Therapeutics Diagnosis Outlook (Revenue - USD Billion, 2018 - 2030)

• MRI
• CT Scan
• Tissue Sampling
• PET-CT scan
• Cerebral Arteriogram
• Lumbar Puncture
• Molecular Testing
• EEG
• Others

Brain Tumor Diagnosis and Therapeutics Therapeutics Outlook (Revenue - USD Billion, 2018 - 2030)

• Surgery
• Radiation Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Others

Brain Tumor Diagnosis and Therapeutics Regional Outlook (Revenue - USD Billion, 2018 - 2030)

• North America
  • U.S
  • Canada
• Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
• Latin America
  • Mexico
  • Brazil
  • Argentina
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa